Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Pembrolizumab and In-situ Injection of CMP-001 in Patients With Relapsed and Refractory Lymphomas

NCT03983668 is registered in ClinicalTrials.gov with Umar Farooq as lead sponsor.

NCT NCT03983668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03983668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Pembrolizumab and In-situ Injection of CMP-001 in Patients With Relapsed and Refractory Lymphomas
Lead sponsor
Umar Farooq
Phase
Phase 1/2
Overall status
Terminated
Start date
January 31, 2020
Completion date
April 8, 2025
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma